psd-502 and dapoxetine

The Post-University Interdisciplinary Association of Sexology (AIUS) has brought together a panel of experts to develop French recommendations for the management of premature ejaculation.. Systematic review of the literature between 01/1995 and 02/2022. Use of the clinical practice guidelines (CPR) method.. We recommend giving all patients with PE psychosexological counseling, and whenever possible combining pharmacotherapies and sexually-focused cognitive-behavioral therapies, involving the partner in the treatment process. Other sexological approaches could be useful. We recommend the use of dapoxetine as first-line, on-demand oral therapy for primary and acquired PE. We recommend the use of lidocaine 150mg/mL/prilocaine 50mg/mL spray as local treatment for primary PE. We suggest the combination of dapoxetine and lidocaine/prilocaine in patients insufficiently improved by monotherapy. In patients who have not responded to treatments with marketing authorisation, we suggest using an off-label SSRI, preferably paroxetine, in the absence of a contraindication. We recommend treating ED before PE in patients with both symptoms. We do not recommend using α-1 blockers or tramadol in patients with PE. We do not recommend routine posthectomy or penile frenulum surgery for PE.. These recommendations should contribute to improving the management of PE.

Topics: Benzylamines; Ejaculation; Humans; Lidocaine, Prilocaine Drug Combination; Male; Premature Ejaculation; Treatment Outcome

Current and upcoming treatment options for premature ejaculation (PE) are of global clinical interest. In 2008, the International Society for Sexual Medicine published an evidence-based definition for PE. While there are no US Food and Drug Administration-approved therapies for PE, the American Urological Association 2004 guidelines state the serotonergic antidepressants paroxetine, sertraline, fluoxetine and clomipramine and the topical lidocaine-prilocaine cream are effective treatment options. However, there are limitations associated with their use, which may be overcome by PE-specific therapies currently in development. Two agents that are in advanced stages of clinical development include: (i) dapoxetine, an on-demand short-acting selective serotonin reuptake inhibitor, and (ii) PSD502, a metered-dose aerosol containing lidocaine and prilocaine, also for on-demand treatment. Another on-demand agent in development is tramadol, a weak opioid that is currently approved for treating pain. Coupled with efficient diagnosis, it is hoped that these newer agents will improve the quality of life for patients who suffer from PE.

Topics: Analgesics, Opioid; Anesthetics, Local; Benzylamines; Ejaculation; Humans; Lidocaine; Lidocaine, Prilocaine Drug Combination; Male; Naphthalenes; Phosphodiesterase 5 Inhibitors; Prilocaine; Serotonin Agents; Sexual Dysfunction, Physiological; Tramadol

Premature ejaculation (PE) is the most common male sexual problem worldwide affecting 22-38% of men. It has a significant morbidity both on patients and their partners, causing distress, anxiety and relationship difficulties. The mainstay of treatment is a combined approach using behavioural therapies and non-licensed medication such as topical anaesthetic preparations, selective serotonin re-uptake inhibitors and phosphodiesterase-5 inhibitors. In recent years, there has been a greater emphasis placed on researching novel treatments and exploring the on-demand use of current preparations. This review provides an overview of current accepted treatments and emerging agents for the use in PE.

Topics: Administration, Oral; Administration, Topical; Anesthetics, Combined; Anesthetics, Local; Benzylamines; Ejaculation; Enzyme Inhibitors; Humans; Lidocaine; Lidocaine, Prilocaine Drug Combination; Male; Naphthalenes; Phosphodiesterase 5 Inhibitors; Prilocaine; Selective Serotonin Reuptake Inhibitors; Sexual Dysfunction, Physiological

Premature ejaculation (PE), the most common male sexual dysfunction, impacts the quality of life of not only the affected male but also his partner. Despite its prevalence, there are currently no United States Food and Drug Administration-approved therapies for PE. In 2004, the American Urological Association published treatment guidelines for PE that recommended the serotonergic antidepressants paroxetine, sertraline, clomipramine and fluoxetine, as well as topical lidocaine-prilocaine cream. None of these treatments were developed for PE, and all have limitations associated with their use. Therapies in development may have advantages over the currently available treatments. These include PSD-502, a metered-dose aerosol of lidocaine and prilocaine used as an on-demand local treatment, and dapoxetine, an on-demand short-acting selective serotonin reuptake inhibitor. Together with a recent, evidence-based definition of PE, these novel therapies should improve sexual function and quality of life in men suffering from PE.

Topics: Animals; Benzylamines; Drug Therapy, Combination; Drugs, Investigational; Ejaculation; Evidence-Based Medicine; Humans; Lidocaine; Lidocaine, Prilocaine Drug Combination; Male; Naphthalenes; Prilocaine; Quality of Life; Sexual Dysfunction, Physiological; Treatment Outcome